EU backs Pfizer’s Hympavzi for hemophilia patients with inhibitors. What changes now?
Hemophilia care is moving beyond factor replacement. Pfizer’s Hympavzi EU expansion tests how far anti-TFPI therapy can scale.
INOVIO’s ASCO and ASGCT updates may sharpen scrutiny of its DNA medicine strategy
INOVIO has a regulatory clock ticking. New INO-3107 and hemophilia A data may show whether its DNA platform can move beyond promise.
Can anti-TFPI drugs like HYMPAVZI reshape the standard of care in inhibitor-positive hemophilia?
Pfizer Inc. has moved a step closer to reshaping the treatment paradigm for one of hemophilia’s most challenging patient subgroups. The company’s investigational therapy HYMPAVZI (marstacimab) demonstrated a 93 percent reduction in bleeding episodes in patients with hemophilia A or B who have developed inhibitors, according to data presented at the 67th American Society of […]